We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A 90-year-old woman was referred by her ophthalmologist ...

Please provide your email address to receive an email when new articles are posted on . A 78-year-old woman was referred to the neuro-ophthalmology service at New England Eye Center for several months ...

We observed 13 patients who developed a subsequent increase in exophthalmometry measurements in the non-proptotic eye within a period ranging from 6 months to 7 years. We believe that such a variable ...

Findings from THRIVE showed treatment with veligrotug led to statistically significant improvements in the signs and symptoms of TED. Topline data were announced from a phase 3 study evaluating ...

Bulging Eyes refers to the abnormal protrusion or sticking out of one or both eyeballs from the eye socket. Normally, there should be no visible white between the colored part of the eye and the upper ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

Dr. Mark A. Matza (Medicine): An 18-year-old man was evaluated at this hospital because of diplopia and proptosis of the left eye. The patient had been well until approximately 33 months before this ...

Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the best low priced pharma stocks to buy now. Earlier on May 20, Viridian Therapeutics announced positive long-term durability data from its Phase 3 ...

DUBLIN--(BUSINESS WIRE)--Horizon Pharma plc (Nasdaq: HZNP) today announced that new data from the Phase 3 confirmatory clinical trial (OPTIC) evaluating the investigational medicine teprotumumab for ...

Of the 655 patients enrolled in this study, 89 (13.5%) (95% confidence interval [CI] 15%-10%) presented with unilateral exophthalmos. Exophthalmometer values in the ...

DUBLIN--(BUSINESS WIRE)--Horizon Pharma plc (Nasdaq: HZNP) today announced that new data from the Phase 3 confirmatory clinical trial (OPTIC) evaluating the investigational medicine teprotumumab for ...